You are here

INTEGRAL MOLECULAR INC

Company Information
Address
25 N 38TH ST STE 800
PHILADELPHIA, PA 19104-5640
United States


https://www.integralmolecular.com/

Information

UEI: DY9KSWE8EJB8

# of Employees: 100


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. High-throughput Discovery of Antibodies against Understudied Membrane Proteins

    Amount: $295,924.00

    ABSTRACT Of the 20,000 genes in the human genome, approximately 4,000 are considered “druggable” by pharmaceuticals. However, less than 10% of these druggable proteins are actually targeted by FDA ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Reagents for Immunologic Analysis of Under-represented Mammalian Models

    Amount: $600,000.00

    Integral Molecular proposes to generate a large panel of pan-reactive monoclonal antibodies (mAbs) against immune cell markers to be used instudies of immune function and responses in nine underrepres ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  3. ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES.

    Amount: $600,000.00

    Using their unique Membrane Proteome Array (MPA)technology, the contractor will screen a comprehensive library of human cell surface proteins to identify novel immunomodulatory targets that regulate d ...

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  4. Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease

    Amount: $447,566.00

    ABSTRACT Aging is the leading risk factor for Alzheimer’s Disease (AD) and many other chronic diseases, with more than 6.5 million cases of AD in the US. Regulating or slowing cellular aging, partic ...

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  5. Development of Claudin MAbs for Treating Solid Tumors

    Amount: $1,309,145.00

    ABSTRACT Solid tumors lead to 580,000 deaths annually in the US, and safe and effective therapeutics for many late- stage solid tumors are lacking. Ovarian cancer alone kills 14,000 people each year, ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  6. Development of Nav1.7 Monoclonal Antibodies for Treating Pain

    Amount: $474,833.00

    ABSTRACT Chronic pain is a significant medical problem, affecting over 50 million Americans and representing the largest cause of disability and disease burden globally. Current pain relief treatments ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  7. Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders

    Amount: $1,809,645.00

    ABSTRACT T cell-mediated autoimmune and chronic inflammatory diseases affect 23 million Americans, corresponding to ~$100B/year in direct healthcare costs. Pharmaceutical advances have enabled the dev ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  8. Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array

    Amount: $1,640,679.00

    ABSTRACT Detailed specificity analysis is critical for drugs, as even minimal off-target binding can cause serious adverse events. As a result, specificity profiling has become an FDA requirement for ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  9. Identifying Agonist MAbs against GPCRs

    Amount: $355,360.00

    ABSTRACT Monoclonal antibodiesMAbsthat target G protein coupled receptorsGPCRsare difficult to isolateand agonist MAbsthat activate GPCRsare even more difficult to discoverIsolating functional MAbs ag ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  10. Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases

    Amount: $414,721.00

    ABSTRACT Alzheimerandapos s diseaseADand other neurodegenerative diseases are a major cause of death and disability for older Americanswith a US prevalence of more thanmillionAs AD currently cannot be ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government